Versicor V-Echinocandin Vs. Fluconazole Phase III Planned For 2001
Executive Summary
Versicor expects to initiate an 18-month Phase III comparative study of its antifungal V-echinocandin versus fluconazole in the first quarter of 2001.
You may also be interested in...
Merck Cancidas
Echinocandin cidal antifungal MK-991 has entered Phase III for fungal infections. The medication is dosed intravenously once-daily, the company said in its annual report. Carbapenem antibiotic MK-826 has also entered Phase III
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials